Solvonis Therapeutics plc (GB:SVNS)
LSE:SVNS
Want to see GB:SVNS full AI Analyst Report?
Top Page
Solvonis Therapeutics
(LSE:SVNS)
Select Model
Select Model
Rating:44Neutral
Price Target:
0.24 p
▼(-30.57% Downside)
Action:Reiterated
Date:05/21/26
The score is weighed down primarily by weak financial performance (recurring losses, cash burn, and a sharp recent revenue decline), only partially offset by a low-debt balance sheet. Technicals are neutral-to-weak with limited momentum, and valuation metrics provide little support due to the lack of meaningful earnings and no dividend yield data.
Positive Factors
Very low leverage
Minimal debt materially reduces solvency risk and preserves financial flexibility over months. With low interest obligations the company can prioritize operational restructuring or targeted investment without immediate refinancing pressure, extending runway during a turnaround.
Negative Factors
Recurring operating/net losses
Sustained operating and net losses erode capital and limit internal funding for growth. Over months this reduces reinvestment capacity, pressures margins if revenues falter, and increases reliance on external financing, complicating any long-term recovery plan.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Minimal debt materially reduces solvency risk and preserves financial flexibility over months. With low interest obligations the company can prioritize operational restructuring or targeted investment without immediate refinancing pressure, extending runway during a turnaround.
Read all positive factors
Solvonis Therapeutics (SVNS) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£16.68M
Dividend YieldN/A
Average Volume (3M)34.43M
Price to Earnings (P/E)―
Beta (1Y)-0.83
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees3
SectorIndustrials
Sector Strength72
IndustryIndustrial - Machinery
Share Statistics
EPS (TTM)-0.01
Shares Outstanding6,806,403,300
10 Day Avg. Volume23,401,787
30 Day Avg. Volume34,434,652
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.44
Price to Sales (P/S)0.00
P/FCF Ratio-4.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Solvonis Therapeutics Business Overview & Revenue Model
Company Description
Solvonis Therapeutics plc, together with its subsidiaries, researches and develops polymer modification technologies and techniques in the United Kingdom, Slovenia, and Europe. The company offers GRAFTABOND, a line of graft/block copolymers for co...
Solvonis Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 587.00K | 542.00K | 219.00K |
| Gross Profit | -18.00K | 0.00 | 0.00 | -134.00K | -51.00K | 55.00K |
| EBITDA | -697.00K | -5.74M | -1.38M | -2.94M | -2.59M | -900.00K |
| Net Income | -961.00K | -5.74M | -1.59M | -3.12M | -2.71M | -954.00K |
Balance Sheet | ||||||
| Total Assets | 3.20M | 7.58M | 3.20M | 2.43M | 4.94M | 3.13M |
| Cash, Cash Equivalents and Short-Term Investments | 757.00K | 1.72M | 757.00K | 155.00K | 1.64M | 598.00K |
| Total Debt | 0.00 | 75.00K | 0.00 | 34.00K | 22.00K | 950.00K |
| Total Liabilities | 119.00K | 1.39M | 119.00K | 408.00K | 385.00K | 2.32M |
| Stockholders Equity | 3.08M | 6.19M | 3.08M | 2.03M | 4.55M | 812.00K |
Cash Flow | ||||||
| Free Cash Flow | -576.00K | -3.27M | -1.13M | -1.47M | -3.08M | -255.00K |
| Operating Cash Flow | -572.00K | -3.27M | -1.13M | -1.24M | -2.36M | -254.00K |
| Investing Cash Flow | -37.00K | 0.00 | -337.00K | -232.00K | -718.00K | -1.00K |
| Financing Cash Flow | 312.00K | 4.23M | 2.08M | 0.00 | 4.13M | 800.00K |
Solvonis Therapeutics Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | £7.52B | 15.58 | 13.71% | 1.93% | -31.27% | -13.26% | |
71 Outperform | £6.62B | 7.91 | 24.91% | 1.29% | 4.25% | 29.89% | |
67 Neutral | £221.91M | 10.69 | 6.13% | 1.02% | 3.36% | 63.32% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
62 Neutral | £615.02M | 24.77 | 6.66% | 4.87% | -9.46% | -57.37% | |
44 Neutral | £16.68M | ― | -62.23% | ― | ― | ― | |
42 Neutral | £77.44M | -9.66 | -12.67% | ― | 42.24% | -432.88% |
* Industrials Sector Average
GB:SVNS
Solvonis Therapeutics
0.27
0.14
107.69%
GB:AVG
Avingtrans
660.00
264.27
66.78%
GB:IMI
IMI plc
2,796.00
874.50
45.51%
GB:MPAC
Mpac Group PLC
257.50
-177.50
-40.80%
GB:MGAM
Morgan Advanced Materials
224.50
20.21
9.89%
GB:SMIN
Smiths Group plc
2,503.00
385.41
18.20%
Solvonis Therapeutics Corporate Events
Business Operations and Strategy
Solvonis CSO to Present on Psychedelic Addiction Therapy at High-Profile NIH Forum
Positive
May 5, 2026
Solvonis Therapeutics announced that its chief scientific officer, Professor David Nutt, will be the sole external speaker at a major U.S. National Institutes of Health addiction research meeting, where he will present on psychedelic therapy for a...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresM&A Transactions
Solvonis pivots strategy to carry lead AUD drug through Phase 3 amid sector tailwinds
Positive
Apr 29, 2026
Solvonis reported that 2025 was a transformative year, completing the Awakn acquisition, integrating its assets, and reshaping itself into a focused CNS therapeutics business with a clinically advanced and more coherent pipeline in addiction and p...
Business Operations and Strategy
Solvonis taps Water Tower Research to lift U.S. profile and investor reach
Positive
Apr 22, 2026
Solvonis Therapeutics has appointed U.S.-based Water Tower Research to sharpen its presence in the American market as it develops small-molecule therapies for central nervous system disorders. The move aligns with the company’s growing pipel...
Business Operations and Strategy
Solvonis Hails U.S. Mental Health Order as Tailwind for CNS Drug Strategy
Positive
Apr 20, 2026
Solvonis Therapeutics welcomed a new U.S. Executive Order aimed at accelerating medical treatments for serious mental illness, viewing it as a strong policy signal that rapid-acting CNS and psychedelic-adjacent therapies are moving into the regula...
Business Operations and Strategy
Solvonis wins second U.S. patent to deepen PTSD therapy IP
Positive
Apr 8, 2026
Solvonis Therapeutics has secured a second U.S. patent covering a chemically distinct monoamine modulator series from its proprietary post-traumatic stress disorder discovery programme, extending protection over compounds that target serotonin, do...
Business Operations and Strategy
Solvonis Wins Key U.S. Patent to Bolster PTSD Drug Pipeline
Positive
Mar 31, 2026
Solvonis Therapeutics has secured a U.S. composition-of-matter patent covering a monoamine modulator compound series from its proprietary PTSD discovery programme, designed to target serotonin, dopamine and noradrenaline transporters. The protecti...
Business Operations and StrategyProduct-Related Announcements
Solvonis names patented PTSD drug candidate SVN‑114 as lead asset
Positive
Mar 10, 2026
Solvonis Therapeutics has selected SVN‑114 as the lead candidate in its Post‑Traumatic Stress Disorder discovery programme, following preclinical work showing balanced modulation of serotonin, dopamine and noradrenaline systems. The co...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.